The Effects of Cannabidiol and ∆-9-THC in Humans

Yale University

Status and phase: Completed; Early Phase 1

Conditions: Healthy

Treatments: Drug: Placebo; Drug: Delta-9-THC; Drug: Cannabidiol

Study type: Interventional

Funder types: Other

Identifiers

NCT01180374

1001006240

Details and patient eligibility

About

Cannabis is the most commonly used illicit substance in the US and herbal cannabis consists of a number of cannabinoids including Δ-9 THC and CBD. This study will characterize the interactive effects of the two major components of cannabis i.e. Δ-9-THC and CBD.

Enrollment: 27 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Exposed to Cannabis at least once in lifetime

Exclusion criteria

• Cannabis Naive

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Quadruple Blind

---

27 participants in 4 patient groups, including a placebo group

Active Canabidiol and Active Delta-9-THC

Experimental group

Treatment:

Drug: Cannabidiol

Drug: Delta-9-THC

Placebo and Active Delta-9-THC

Placebo Comparator group

Treatment:

Drug: Placebo

Drug: Delta-9-THC

Drug: Placebo

Active Cannabidiol and Placebo

Experimental group

Treatment:

Drug: Cannabidiol

Drug: Placebo

Drug: Placebo

Placebo and Placebo

Placebo Comparator group

Treatment:

Drug: Placebo

Drug: Placebo